Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first i...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncoimmunology
Hlavní autoři: Rentsch, Cyrill A., Bosshard, Piet, Mayor, Grégoire, Rieken, Malte, Püschel, Heike, Wirth, Grégory, Cathomas, Richard, Parzmair, Gerald P., Grode, Leander, Eisele, Bernd, Sharma, Hitt, Gupta, Manish, Gairola, Sunil, Shaligram, Umesh, Goldenberger, Daniel, Spertini, François, Audran, Régine, Enoiu, Milica, Berardi, Simona, Hayoz, Stefanie, Wicki, Andreas
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2020
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7185202/
https://ncbi.nlm.nih.gov/pubmed/32363120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1748981
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky